Kaïssa Ouali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaïssa Ouali has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Christophe Massard
Gustave Roussy Cancer Institute, Paris-Saclay University, DITEP, Villejuif, France
47 shared publications - Sophie Postel-Vinay
National Institute of Health and Medical Research INSERM U981 and Drug Development Department, Gustave Roussy, Paris Saclay University, Villejuif, France
46 shared publications - Archana Roy
10AstraZeneca, Gaithersburg, Maryland
35 shared publications - Arthur W. Lambert
Translational Medicine, AstraZeneca, Waltham, Massachusetts
35 shared publications - Christos E. Kyriakopoulos
University of Wisconsin–Madison 17 Department of Medicine Madison, Wisconsin
35 shared publications - Eduardo Castañón Álvarez
Clinica Universidad de Navarra 4 Department of Oncology Pamplona, Spain
35 shared publications
Latest Publications
- 14 October 2026
- Published by Elsevier in Annals of Oncology
Emerging therapeutic targets and early-phase drug development in gynecological malignancies
- 14 October 2026
- Published by Elsevier in Annals of Oncology
Emerging therapeutic targets and early-phase drug development in gynecological malignancies
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
CONSORT flow diagram of participant enrollment and study analysis. *Trial identifiers are confidential and could not be disclosed. DITEP, Drug Development Department.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
CONSORT flow diagram of participant enrollment and study analysis. *Trial identifiers are confidential and could not be disclosed. DITEP, Drug Development Department.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for OS according to the GRIm score. OS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median OS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for OS according to the GRIm score. OS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median OS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for PFS according to the GRIm score. PFS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median PFS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot, except for C, in which every patient from the high-risk group had progressive disease before the first in the other group.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan–Meier curves for PFS according to the GRIm score. PFS according to the GRIm score in the overall cohort (A) and in patients with solid tumors (B) and with hematologic malignancies (C). Median PFS for each risk group, HR, 95% CI, and P value of the comparison of the two GRIm risk groups using Cox regression models are displayed on each plot, except for C, in which every patient from the high-risk group had progressive disease before the first in the other group.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of OS.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of OS.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for OS according to the GRIm score in patients treated with TCE in monotherapy.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for OS according to the GRIm score in patients treated with TCE in monotherapy.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of PFS.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Multivariate analysis shows the GRIm score is independently prognostic of PFS.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for PFS according to the GRIm score in patients treated with TCE in monotherapy.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Kaplan Meier curves for PFS according to the GRIm score in patients treated with TCE in monotherapy.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients.
- Open Access
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients according to the GRIm score.
- 7 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials
Baseline characteristics of the patients according to the GRIm score.